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Introduction
Nowadays, patients scheduled for coronary artery by-
pass grafting (CABG) present with multiple comorbidities 
that may increase the incidence of complications and 
worsen the outcome. Concomitant and significant carotid 
stenosis is observed in around 8–14% of patients eligible 
for surgical myocardial revascularization [1]. In such cases, 
postoperative neurological complications and higher mor-
tality are observed, especially in individuals with a history 
of prior stroke or transient ischemic attack (TIA) [2]. Cur-
rently, in patients qualified for CABG, prophylactic carotid 
revascularization should be considered in symptomatic 
cases and may be considered in asymptomatic ones after 
a multidisciplinary discussion [3]. Nevertheless, there are 
no strict guidelines regarding the timing and the modality 
of both procedures. Based on observational studies, com-
bined 1-day hybrid intervention may reduce the interstage 
myocardial infarction (MI) rate observed in patients un-
dergoing staged procedures [4, 5]. In spite of there being 
only a few available reports so far, this approach provides 
satisfactory early and long-term outcomes and could be 
considered as an especially attractive alternative for pa-
tients with advanced or unstable coronary artery disease, 
which results in high risk of cardiac complications during 
the carotid procedure [6, 7].
Aim
The aim of the study was to assess the surgical safety of 
one-day carotid artery stenting (CAS) combined with CABG.
Material and methods
In a  retrospective cohort study we enrolled 57 con-
secutive patients (42 males, 15 females; mean age: 70.8 
±6.9 years) with a median EuroSCORE II of 2.4% (1.7–3.0) 
who were scheduled for hybrid one-day CAS combined 
with CABG based on a multidisciplinary Heart Team de-
cision, including neurological and vascular consultations 
[3]. All patients required urgent (definitive procedure 
within the same hospitalization) cardiac surgery and had 
concomitant carotid artery stenosis qualifying them for 
revascularization (Table I A). 
Carotid artery stenting was performed under local 
anesthesia through percutaneous transfemoral access 
using different embolic protection devices and differ-
ent stent types according to the tailored CAS algorithm 
[8–10]. After the procedure, the patient was immediately 
transferred to the cardiac operating room, where addi-
tional neurological assessment was performed. In case 
of any focal deficits, the protocol assumed postponing 
the surgery until further evaluation. In patients with es-
pecially high risk of cardiac complications, the procedure 
was performed in a  hybrid operating room under gen-
eral anesthesia, and started with a sternotomy. The su-
tures for emergent cannulation were placed and then the 
CAS procedure and subsequent CABG were performed. 
This approach, with a cardiopulmonary bypass (CPB) on 
stand-by, secured the possibility to go on-pump emer-
gently in case of hemodynamic instability or sudden car-
diac arrest. In these patients neurological assessment 
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was performed as soon as possible after weaning off the 
sedation following completion of a combined procedure.
All CABG procedures were performed via a  median 
sternotomy and with CPB. Heparinization was first start-
ed during the CAS procedure with 1 mg/kg intra-arterially 
as a bolus with a target activated clotting time (ACT) of 
250 s. Activated clotting time was then assessed on the 
admission to the operating room and an additional dose 
of heparin was administered in order to achieve ACT 
≥ 480 s before CPB start. Heparinization was subse-
quently reversed by protamine 1 : 1. 
Prior to the procedure all patients were receiving as-
pirin (75 mg orally) according to the primary prevention 
algorithm. Postoperative antiplatelet management was 
obtained with a  loading dose of clopidogrel (300 mg) 
administered through a nasogastric tube within the first 
hours after surgery. The decision to institute clopidogrel 
was made based on the chest-tube output volume. From 
the next postoperative day, all patients received dual an-
tiplatelet therapy with clopidogrel (75 mg orally) and as-
pirin (75 mg orally) for a duration of 1 month (Figure 1).
All patients were followed up as part of a standard 
cardiac surgery out-patient clinic appointment 1 month 
after surgery.
Statistical analysis
Statistical analysis was performed using IBM SPSS 
software. Results were presented based on the parame-
ters of descriptive statistics, including mean values and 
Figure 1. Postoperative antiplatelet management
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Table I. Baseline characteristics
A. Preoperative outcome
Variables Analyzed population, N = 57
Age [years] 70.8 ±6.9
Male sex, n (%) 42 (73.7)
BMI [kg/m2] 28.3 ±4.7
Diabetes, n (%) 22 (38.6)
Hypertension, n (%) 53 (93)
Hyperlipidemia, n (%) 55 (96.5)
Smoking, n (%) 20 (35.1)
Previous stroke or TIA, n (%) 15 (26.3)
Previous MI, n (%) 18 (31.6)
CKD, n (%) 14 (24.6)
Preoperative creatine level [μmol/l] 91.4 ±23.5
Preoperative platelet count [× 103/μl] 234.3 ±74.3
Three-vessel disease, n (%) 47 (82.5)
LM disease, n (%) 22 (38.6)
EuroSCORE II 2.7 ±1.3
B. Postoperative outcome
Variables Analyzed population, N = 57
30-day all-cause death, n (%) 0 (0)
30-day MACCE, n (%) 0 (0)
Chest-tube output before clopidogrel 
administration [ml/kg/h]
0.21 (0.12–0.38)
Chest-tube output after clopidogrel 
administration [ml/kg/h]
0.36 (0.24–0.59)
Postoperative platelet count [×103/μl] 150.7 ±50.3
BE, n (%) 11 (19.3)
Re-exploration for bleeding, n (%) 5 (8.7)
Cardiac tamponade, n (%) 0 (0)
Pleural hematoma, n (%) 2 (3.5)
Active bleeding, n (%) 1 (1.8)
PRBC transfusion (≥ 5 units), n (%) 6 (10.5)
FFP transfusion (≥ 5 units), n (%) 8 (14)
GI bleeding, n (%) 0 (0)
AKI, n (%) 13 (22.8)
Postoperative creatinine level [μmol/l] 106.7 ±49.2
Data shown as mean ± SD or as median (IQR), number (percentage). BMI – body 
mass index, TIA – transient ischemic attack, MI – myocardial infarction, CKD – 
chronic kidney disease, LM – left main, MACCE – major adverse cardiac and 
cerebrovascular events, BE – bleeding event, PRBC – packed red blood cells, FFP 
– fresh frozen plasma, GI – gastrointestinal, AKI – acute kidney injury. MACCE 
was defined as cardiac death, cerebrovascular death, non-fatal cardiac arrest, 
acute myocardial infarction, stroke, or TIA. BE was defined as re-exploration for 
bleeding, pleural hematoma, cardiac tamponade, active bleeding (chest-tube 
output > 1.5 ml/kg/h), massive blood product transfusions (≥ 5 units of PRBC or 
FFP), or gastrointestinal bleeding within 30 days after surgery. AKI was defined 
as an increase in serum creatinine by ≥ 26.5 µmol/l within 48 h after surgery.
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standard deviations, or median values and quartiles, 
as appropriate. Categorical variables were presented as 
percentages. Univariate logistic regression was used to 
determine risk factors for the end-points. A p-value less 
than 0.05 was considered significant.
Results
We did not have to postpone or cancel the surgery 
due to neurological complications in any of the sched-
uled cases. The median time from the end of surgery to 
the loading dose of clopidogrel was 8 h.
No 30-day mortality or MACCE were observed and 
patients were usually discharged on postoperative day 8. 
Postoperative chest-tube output significantly in-
creased after receiving clopidogrel (0.2 vs. 0.4 ml/kg/h; 
p < 0.001); however, active bleeding was observed only 
in 3 (5.3%) patients. BE occurred in 11 (19.3%) individ-
uals but re-exploration for bleeding was required only in 
5 (8.7%) cases (Table I B).
In a  univariate logistic regression model, platelet 
count ≤ 110 000 at the cessation of CPB increased the 
risk of BE (OR = 5.7 (1.39–23.36); p = 0.016); however, no 
impact was found with respect to preoperative platelet 
count or the platelet count decrease during the CPB.
Acute kidney injury was observed in 13 (22.8%) pa-
tients and the risk increased with the duration of CPB 
based on a  univariate logistic regression model (OR = 
1.41 (1.06–1.88); p = 0.02 for every 10 min). In all cases 
effective diuresis was successfully maintained with intra-
venous loop diuretics.
Discussion
The proper timing and modality of multisite revas-
cularization remains an unresolved issue. Nevertheless, 
current guidelines underline the necessity to individual-
ize patients’ care [3]. The approach proposed in this study 
appears to be a satisfactory alternative for patients with 
severe carotid stenosis and coronary artery disease re-
quiring urgent surgical intervention. However, in spite of 
the potential benefits, which include a decrease of cardi-
ac and neurological complications, there are a  few ma-
jor concerns regarding the management within the early 
postoperative period that necessitate a multidisciplinary 
discussion. 
Firstly, patients after hybrid procedures require quick 
implementation of a dual antiplatelet therapy (DAPT), in-
cluding a loading dose of clopidogrel [6]. In spite of the 
fact that chest-tube output significantly increased after 
clopidogrel administration, the proposed approach ap-
pears to be safer than operating on patients in whom 
DAPT is already instituted, i.e. in case of a staged mul-
tisite revascularization [3, 11]. In the study, the surgical 
criteria for active bleeding were met only in 3 individ-
uals. Therefore, in spite of a very high reported BE rate 
(19.3%), in comparison to other studies, we still consider 
the proposed procedure to be a safe method in terms of 
bleeding complications. Our endpoint included adverse 
events that are usually not reported, so we could achieve 
the highest possible sensitivity. Moreover, out of all BE, 
re-exploration was observed only in 5 cases, providing 
an acceptable rate of 8.7% that is comparable to our cen-
ter’s outcome after standard CABG [12]. 
Nevertheless, the occurrence of BE was difficult 
to predict, and based on the univariate analysis, the 
only factor increasing the risk was the platelet count 
≤ 110 000 at the cessation of CPB. Although no tests for 
platelet activity were performed postoperatively before 
or after instituting clopidogrel, based on the literature, 
it is known that 300 mg of clopidogrel usually inhibits 
around 50% of platelets at 4 h after administration [13]. 
Therefore, in those individuals with a count of 110 000 
at the cessation of CPB, only around 55 000 platelets are 
expected to be active, which is not sufficient to provide 
optimal hemostasis within the early perioperative peri-
od. Moreover, according to the EACTS guidelines, micro-
vascular bleeding observed at the end of a cardiac proce-
dure is an indication for platelet transfusion in patients 
receiving antiplatelet therapy [14]. Although acute stent 
thrombosis is rarely observed in terms of carotid revas-
cularization, platelet transfusion should be administered 
with caution in these individuals. Therefore, such pro-
cedures require very precise intraoperative hemostasis, 
which limits the availability only to experienced cardiac 
centers.
Another expected complication, due to the combined 
effect of both intravenous contrast administration and 
CPB, was AKI. Although it occurred in almost 30% of the 
cases, it is consistent with the rates reported after stan-
dard cardiac surgery procedures [15]. Moreover, in none 
of the patients was hemodialysis required, which proves 
the safety of the procedure in terms of potential renal 
impairment. 
Nevertheless, despite these complications and high 
perioperative risk assessed with the EuroSCORE II, we 
observed excellent 30-day outcomes with no MACCE and 
no mortality. These excellent results suggest that in the 
case of CAS combined with immediate CABG, antiplate-
let therapy managed with a loading dose of clopidogrel 
within the first 24 h and regular DAPT starting on the 
next postprocedural day is a safe approach, as no early 
thrombosis was observed in implanted stents. Presum-
ably, prolonged ACT achieved for on-pump CABG guar-
antees the safety of such a  delay in introducing DAPT 
without increasing the risk of intracranial bleeding com-
plications.
Limitations 
The study is a retrospective analysis of a small sam-
ple size from a single center. As only one factor was de-
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termined to be significant in univariate regression mod-
els, multivariate analyses were not performed.
Conclusions
Performing one-day CAS combined with subsequent 
CABG is feasible in a specialized cardiac center and can 
be performed safely by an experienced multidisciplinary 
team with satisfactory early results and a  low surgical 
complication rate.
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